Navellier & Associates’s Enanta Pharmaceuticals ENTA Stock Holding History

Navellier & Associates’s Portfolio ENTA Stock Details ENTA Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2020 Q2	–	Sell	-6,300	Closed	-$324K	–	243
2020 Q1	$324K	Hold	6,300	–	–	0.08%	172
2019 Q4	$389K	Sell	6,300 -744	-11%	-$46.1K	0.06%	208
2019 Q3	$423K	Sell	7,044 -2,623	-27%	-$195K	0.07%	188
2019 Q2	$816K	Sell	9,667 -970	-9%	-$87.3K	0.13%	146
2019 Q1	$1.02M	Sell	10,637 -18,957	-64%	-$1.7M	0.16%	124
2018 Q4	$2.1M	Buy	29,594 +3,201	+12%	+$245K	0.36%	68
2018 Q3	$2.26M	Buy	26,393 +7,514	+40%	+$753K	0.29%	99
2018 Q2	$2.19M	Buy	18,879 +9,227	+96%	+$921K	0.3%	99
2018 Q1	$781K	Buy	+9,652	New	+$743K	0.12%	154
2015 Q1	–	Sell	-28,759	Closed	-$1.46M	–	356
2014 Q4	$1.46M	Buy	+28,759	New	+$1.29M	0.07%	83

Other funds holding ENTA

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

FCM

Farallon Capital Management San Francisco, California $17.5B AUM 50.95% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

KAM

Krensavage Asset Management New York $256M AUM 69.63% 1-Year Est. Return

Dimensional Fund Advisors Austin, Texas $481B AUM 30.42% 1-Year Est. Return

Ameriprise Minneapolis, Minnesota $432B AUM 30.22% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Navellier & Associates's ENTA Position: Q2 2020 in Review

Navellier & Associates sold out of Enanta Pharmaceuticals (ENTA) in Q2 2020, closing a stake of 6,300 shares — an estimated $324K sold.

Navellier & Associates first reported a position in ENTA in Q4 2014 and held it in 10 quarters. The position peaked at $2.26M in Q3 2018. 180 funds tracked by Wall St. Rank hold ENTA as of Q2 2020.

Navellier & Associates reported no remaining Enanta Pharmaceuticals position as of Q2 2020 after selling out during the quarter.
Navellier & Associates sold 6,300 Enanta Pharmaceuticals shares in Q2 2020, an estimated $324K.
Navellier & Associates first reported a position in Enanta Pharmaceuticals in Q4 2014 and held it in 10 quarters.
Navellier & Associates's Enanta Pharmaceuticals position peaked at $2.26M in Q3 2018.
180 funds tracked by Wall St. Rank held Enanta Pharmaceuticals as of Q2 2020.

Based on Navellier & Associates's 13F filing for Q2 2020, filed 12 Aug 2020.